<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114306">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01894867</url>
  </required_header>
  <id_info>
    <org_study_id>MMC13247-12CTIL</org_study_id>
    <nct_id>NCT01894867</nct_id>
  </id_info>
  <brief_title>Magnesium in Liver Cirrhosis</brief_title>
  <official_title>Magnesium Deficiency in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <authority>Israel: Clalit Health Services</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have shown in patients magnesium deficiency with liver cirrhosis.

      Patients with liver cirrhosis showed considerably reduced muscle strength and muscle
      magnesium.

      We suggest addition of magnesium to patients with established cirrhosis in order to reduce
      the neuromuscular and neuropsychiatric manifestations of chronic liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnesium is the fourth most abundant cation in the body and plays an important
      physiological role in many of its functions.

      There are no readily available and easy methods to assess magnesium status but it is
      estimated that magnesium deficiency is a common problem.

      Magnesium deficiency can cause a wide variety of features including hypocalcaemia,
      hypokalaemia and cardiac and neurological manifestations. Chronic low magnesium state has
      been associated with a number of chronic diseases including diabetes, hypertension, coronary
      heart disease, and osteoporosis.

      There are not enough studies on magnesium status in chronic cirrhotics who may be in
      depletion. However , several studies have shown in patients magnesium deficiency with liver
      cirrhosis.  Patients with liver cirrhosis showed considerably reduced muscle strength and
      muscle Mg . Magnesium may have a role in the neuromuscular and neuropsychiatric
      manifestations of chronic liver disease (hepatic encephalopathy and muscle cramps).

      The use of magnesium as a therapeutic agent in asthma, myocardial infarction, and
      pre-eclampsia is also discussed. We suggest addition of magnesium to patients with
      established cirrhosis in order to reduce the neuromuscular and neuropsychiatric
      manifestations of chronic liver disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in minimal hepatic encephalopathy</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in muscle weakness</measure>
    <time_frame>6 weeks after intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>chang in other cirrhosis parameters</measure>
    <time_frame>6 weeks after intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in liver function test (AST ALT GPT GGT ALBUMIN INR) change in magnesium level</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>LIVER CIRRHOSIS</condition>
  <arm_group>
    <arm_group_label>magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will get magnesium for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will get placebo for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>magnesium</intervention_name>
    <description>supply magnesium oxide for 6 weeks</description>
    <arm_group_label>magnesium</arm_group_label>
    <other_name>magnesium oxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with liver cirrhosis

        Exclusion Criteria:

          -  pregnant women

          -  Patients with acute or chronic renal failure (cr&gt;1.5)

          -  Congestive heart failure NYHA 3-4

          -  Patient with active cancer

          -  Patients with dementia or mental retardation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>keren cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>keren cohen, MD</last_name>
    <phone>972522237442</phone>
    <email>kerenc03@walla.co.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yona kitay, MD</last_name>
    <email>yonaki@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>liver outpatients clinic, Meir medical center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>keren cohen, MD</last_name>
      <phone>97297471560</phone>
      <email>keren.cohen@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>keren cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>YONA KITAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>July 11, 2013</lastchanged_date>
  <firstreceived_date>July 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LIVER CIRRHOSIS</keyword>
  <keyword>MAGNESIUM</keyword>
  <keyword>MINIMAL ENCEPHALOPATHY</keyword>
  <keyword>MUSCLE WEAKNESS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Magnesium Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Magnesium Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
